Examkin

Soru

Zorluk: ZorInfectious Diseases

Match each of the following hospital-acquired pathogen profiles with the most appropriate targeted antimicrobial therapy. Assume the patient has no reported drug allergies and normal renal function.

  • Bloodstream infection with Escherichia coli demonstrating resistance to ceftriaxone but in vitro susceptibility to piperacillin-tazobactamMeropenem
  • Bloodstream infection with Enterobacter cloacae demonstrating initial in vitro susceptibility to ceftriaxone, ceftazidime, and cefepimeCefepime
  • Ventilator-associated pneumonia with Acinetobacter baumannii demonstrating broad resistance to antipseudomonal penicillins and carbapenemsAmpicillin-sulbactam
  • Hospital-acquired pneumonia with Stenotrophomonas maltophiliaTrimethoprim-sulfamethoxazole

Cevap

Escherichia coli (ESBL) pairs with Meropenem; Enterobacter cloacae pairs with Cefepime; Acinetobacter baumannii pairs with Ampicillin-sulbactam; Stenotrophomonas maltophilia pairs with Trimethoprim-sulfamethoxazole.
Each pathogen requires specific stewardship knowledge: Meropenem is necessary for ESBL Enterobacterales due to proven mortality benefits; Cefepime resists AmpC beta-lactamase hydrolysis making it ideal for Enterobacter; Ampicillin-sulbactam works against Acinetobacter because sulbactam directly binds to penicillin-binding proteins of this specific organism; and Trimethoprim-sulfamethoxazole bypasses the intrinsic carbapenemases produced by Stenotrophomonas.

Adım Adım Çözüm

1
Identify the resistance phenotype of the Escherichia coli isolate.
Recognized as an ESBL producer based on ceftriaxone resistance.
Requires carbapenem therapy (Meropenem) for invasive disease to reduce mortality, overriding in vitro susceptibility to piperacillin-tazobactam.
2
Evaluate the resistance risk for the Enterobacter cloacae isolate.
Recognized as a high-risk AmpC-producing organism.
Requires an AmpC-stable cephalosporin (Cefepime) or a carbapenem; ceftriaxone must be avoided due to the risk of rapid resistance induction.
3
Determine the optimal agent for carbapenem-resistant Acinetobacter baumannii.
Selected Ampicillin-sulbactam.
Sulbactam provides specific bactericidal activity against Acinetobacter, acting as the primary therapeutic component rather than just a beta-lactamase inhibitor.
4
Identify the first-line therapy for Stenotrophomonas maltophilia.
Selected Trimethoprim-sulfamethoxazole.
This organism is intrinsically resistant to carbapenems via chromosomal metallo-beta-lactamases, making Trimethoprim-sulfamethoxazole the drug of choice.

Anahtar Kavram

Antimicrobial stewardship and targeted therapy selection for multidrug-resistant nosocomial pathogens (ESBL, AmpC, CRAB, and Stenotrophomonas).
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru